Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease
01 févr. 2021 07h30 HE
|
Spark Therapeutics, Inc.
First participant dosed in the RESOLUTESM trial, a Phase 1/2 dose-escalation study of SPK-3006 Enrollment of approximately 20 total study participants is ongoing PHILADELPHIA, Feb. 01, 2021 (GLOBE...
Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy Officer
16 nov. 2020 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
Spark Therapeutics Deepens Drug Development Expertise in Hematology and Rare Disease with Appointment of Gallia G. Levy, M.D., Ph.D., as Chief Medical Officer
10 août 2020 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
Spark Therapeutics Recognized for Fourth-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
03 août 2020 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress
12 juil. 2020 10h15 HE
|
Spark Therapeutics, Inc.
All five participants in the 5x1011 vg/kg and 1×1012 vg/kg dose cohorts and seven participants in the 2×1012 vg/kg dose show an acceptable safety profile, stable and durable factor VIII expression and...
Study Demonstrating Role of IdeS in Enabling of Gene Therapy in the Presence of Neutralizing Anti-AAV Antibodies Published in Nature Medicine
01 juin 2020 11h00 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, June 01, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced...
Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product
25 oct. 2019 09h54 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living with Inherited Retinal Diseases (IRDs) Access Genetic Testing
18 sept. 2019 07h30 HE
|
Spark Therapeutics, Inc.
Paralympic, blind skier declared Eye Want 2 Know® and pursued genetic testing to uncover the genetic cause of her retinitis pigmentosa (RP), an IRD Spark Therapeutics unveils enhanced ID YOUR IRD®...
Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders
27 août 2019 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
Spark Therapeutics Announces Sponsorship of Believe Limited’s First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation’s Bleeding Disorders Conference
17 avr. 2019 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, April 17, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...